Global Cord Blood Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CORBF research report →
Price Chart
About the company
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes.
- CEO
- Ting Zheng
- IPO
- 2007
- Employees
- 1,202
- HQ
- Hong Kong, HK
Get TickerSpark's AI analysis on CORBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $127.35M
- P/E
- 1.55
- Fwd P/E
- 0.92
- PEG
- -0.20
- P/S
- 0.69
- P/B
- 0.16
- EV/EBITDA
- -8.84
- Div Yield
- 0.00%
- Gross Margin
- 85.26%
- Op Margin
- 48.97%
- Net Margin
- 40.30%
- ROE
- 10.82%
- ROIC
- 6.26%
Latest fiscal year · YoY change
- Revenue
- $1.24B+7.2%
- Gross Profit
- $1.06B+8.1%
- Op Income
- $608.87M
- Net Income
- $501.06M-1.4%
- EPS
- $4.12-1.4%
- OCF Growth
- -2.7%
- FCF Growth
- -2.6%
- 52W High
- $1.75
- 52W Low
- $0.20
- 50D MA
- $0.94
- 200D MA
- $0.95
- Beta
- -0.77
- RSI (14)
- 48
- Avg Volume
- 18.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Global Cord Blood posted mid-single-digit subscriber growth and solid profit growth in fiscal Q3, while warning that COVID disruptions and China’s birth-rate decline remain key headwinds.· March 1, 2022
- Q3 revenue rose 9% year over year to about RMB 317 million, with gross profit up 10% to about RMB 270 million and gross margin steady at 85%.
- Net income attributable to shareholders increased 15% year over year to RMB 134 million, and basic/diluted EPS was RMB 1.11.
- New subscribers grew 6.6% year over year to 18,985; cumulative subscribers surpassed 555,000 by the end of December 2021.
- Management said COVID lockdowns and tighter hospital access continued to hurt client access and conversion, but new subscriber growth was in line with expectations.
- Full-year new subscriber guidance was reaffirmed at around 75,000, described as the higher end of prior guidance.
Revenue increased 9% year over year to approximately RMB 317 million. Gross profit rose 10% to approximately RMB 270 million, with gross margin flat at 85%. Operating income increased about 21% year over year to approximately RMB 150 million, and operating margin improved to 47% from 43%. Non-GAAP operating income was RMB 162 million, up about 19%, with non-GAAP operating margin at 51% versus 47%. Net income attributable to shareholders increased 15% year over year to RMB 134 million, net margin improved to 42% from 40%, and basic/diluted EPS was RMB 1.11. New subscribers were 18,985, up 6.6% year over year, and accumulated subscribers exceeded 555,000. For the quarter, management said new subscriber numbers in fiscal 2022 are expected to be around the higher end of prior guidance at 75,000.
The CEO’s remarks focused on operating through a difficult environment: winter COVID-19 outbreaks, localized lockdowns, and stricter hospital access continued to weigh on client acquisition and conversion. Even so, management said subscriber growth held up and was in line with expectations. Strategically, the company said it is closely monitoring regulatory developments, especially the still-unresolved licensing regime for China’s cord blood banking industry, while also looking for ways to diversify beyond its core business.
The CFO highlighted broad-based financial improvement driven by higher processing and storage revenues. Processing fees and other services rose about 10% year over year to RMB 181 million, storage fee revenue increased 8% to RMB 136 million, and gross profit grew 10% to about RMB 270 million while gross margin stayed at 85%. Operating discipline helped as sales and marketing expense fell 5% to RMB 66 million; G&A rose 8% to RMB 47 million; cash flow details and capital allocation were not discussed in this call.
The only analyst question asked about the geographic mix of new subscribers and payment-option mix. Management said about 11% of new subscribers came from Beijing, 67% from Guangdong, and 22% from Zhejiang. On payment methods, about 30% used one option that was not clearly transcribed, 38% chose upfront payment, and 32% chose installment payment.
The quarter showed that the business is still growing profitably: revenue, gross profit, operating income, and net income all increased year over year, while gross margin remained high at 85%. Management also sounded confident enough to keep full-year subscriber guidance at the higher end of the prior range, despite COVID and demographic pressure.
Management repeatedly flagged ongoing headwinds from COVID-19 restrictions and the long-term decline in births, both of which can hurt client access and demand. Regulatory uncertainty also remains a major risk, since the National Health Commission has not yet updated the licensing regime for the cord blood banking industry.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.0%
- Shares Outstanding
- 133.91M
- Float Shares
- 116.52M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 14 | MCCARTHY KENT C | buy | 60,000 |
| Feb 26, 13 | MCCARTHY KENT C | sell | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CORBF coverage
Recent articles, reports, and earnings notes.
No research on CORBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CORBF report →Global Cord Blood Corporation Investors With Losses Are Urged By The Schall Law Firm To Start Communication Be Mindful Of The Deadline In This Case
accesswire.com · Jun 25
The Schall Law Firm Encourages Global Cord Blood Corporation Investors With Losses To Initiate Communication Be Conscious Of The Time Limit In This Situation
accesswire.com · Jun 24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines - CORBF
prnewswire.com · Jun 24
CO, CORBF DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Global Cord Blood Corporation Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action – CO, CORBF
globenewswire.com · Jun 24
Investors Who Have Incurred Losses In Global Cord Blood Corporation Are Encouraged By The Schall Law Firm To Reach Out Please Be Mindful Of The Deadline In This Matter
accesswire.com · Jun 23
Investors Who Have Sustained Losses In Global Cord Blood Corporation Are Urged By The Schall Law Firm To Make Contact Please Be Aware Of The Deadline In This Case
accesswire.com · Jun 22
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Global Cord Blood Corporation of Class Action Lawsuit and Upcoming Deadlines – CORBF
globenewswire.com · Jun 22
CO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud Lawsuit
prnewswire.com · Jun 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.